Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | RHEB | Q15382 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014183 | 0.86 | PTGER4 (0.44) | PTGER1MRGPRX4RHEBMAPK1L3MBTL1 | |
| SCHEMBL4012447 | 0.79 | MCL1 (0.52) | NR4A2MRGPRX4MAOAMAOBALKBH1 | |
| SCHEMBL11463145 | 0.78 | KMT2A (0.49) | MAPK1L3MBTL1PTGER4PTGER2 | |
| SCHEMBL30990046 | 0.78 | KMT2A (0.49) | MAPK1L3MBTL1PTGER4PTGER2 | |
| SCHEMBL4020114 | 0.78 | PTGER4 (0.53) | PTGER1MRGPRX4SLC6A4PTGER4PTGER2 | |
| SCHEMBL1284749 | 0.78 | PTGER4 (0.75) | PTGER4PTGER2 | |
| SCHEMBL691764 | 0.78 | PTGER4 (0.61) | PTGER1MAPK1PTGER4PTGER2 | |
| SCHEMBL11452714 | 0.76 | CYP1A2 (0.45) | L3MBTL1PTGER4PTGER2 | |
| SCHEMBL11551863 | 0.75 | PTGER1 (0.43) | PTGER1XDHPTGER4PTGER2 | |
| SCHEMBL6725152 | 0.75 | MRGPRX4 (0.55) | NR4A2PTGER1MRGPRX4RHEBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756043-B1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1756043-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005105733-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | OPRL1, PTGER1, OPRM1 | NR4A2 622/4885PTGER1 2/4885MRGPRX4 105/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | NR4A2 235/4885PTGER1 5/4885MRGPRX4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.